making precision decisions in the treatment of nsclc with common and uncommon egfr mutations
Published 6 months ago • 581 plays • Length 52:36Download video MP4
Download video MP3
Similar videos
-
45:57
refining precision decisions in nsclc with common and less common egfr mutations
-
1:07:31
precision decisions in genomic testing and targeted treatment of nsclc
-
1:05:12
new horizons in egfr-mutated nsclc: broadening the impact of precision testing
-
58:24
time for even more precision in testing and treatment of egfr-mutated nsclc
-
53:55
advancing care for patients with egfr mutation–positive nsclc: precision medicine strategies
-
41:59
testing for common and uncommon egfr mutations to guide egfr-targeted therapy in nsclc
-
1:21
detectability of uncommon egfr mutations in nsclc: ngs versus pcr
-
59:19
precision oncology in early-stage lung cancer, with adjuvant egfr-targeted therapy leading the way
-
41:23
multimodal management of early-stage nsclc: egfr-targeted therapy in perioperative settings
-
1:02:08
improving outcomes in molecularly altered nsclc through precision testing and treatment
-
1:01:27
molecular testing for egfr mutations: what pathologists need to know
-
1:02:40
new milestones and changing standards of care in early egfr-mutated nsclc
-
59:37
refining biomarker testing and targeted treatment of nsclc with egfr mutations
-
2:05
changing the treatment landscape for patients with nsclc and egfr mutations
-
1:02:02
improving outcomes in molecularly altered nsclc through precision testing and treatment
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
1:00:20
it’s precisely the time for more precision in genomic testing and targeted treatment of nsclc
-
2:45
activity of egfr tkis in patients with nsclc with uncommon egfr mutations
-
17:45
individual treatments for individual egfr mutations